This year, thanks to the hard work of our dedicated and passionate team, we successfully optimized our therapeutic candidate, achieving with a single product efficacy equal to or greater than three monoclonal antibodies — without their drawbacks — and significantly improving brain penetration. 🧠
This breakthrough paves the way for a revolutionary treatment for Alzheimer’s disease and related disorders, bringing hope to millions of patients worldwide.
We want to express our heartfelt thanks to our partners and investors. Every project, every collaboration, and every shared effort brings us closer to our mission.
With only 9 people in the team, we have delivered remarkable results — proof that a small team can make a big impact. 💥 We are confident that 2026 will shine even brighter !
Wishing you all joyful holidays and a new year filled with hope and success. 🎄
The Amyl Team
